LIGAND PHARMACEUTICALS INCORPORATED (LGND) FY2026 Q2 P&L / Income Statement

LIGAND PHARMACEUTICALS INCORPORATED (LGND) FY2026 Q2 P&L / Income Statement

Income statement for 2026-04-01 through 2026-06-30. View: Product and service (14 categories). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Total revenues and income

63,693,000 US dollars

Cost of revenue (calculated)

11,311,000 US dollars

Gross profit (calculated)

52,382,000 US dollars

Operating expenses (calculated)

43,791,000 US dollars

Operating income (loss)

8,591,000 US dollars

Total non-operating income (expenses), net

55,713,000 US dollars

Income (loss) before income taxes

64,304,000 US dollars

Income tax (expense) benefit

15,796,000 US dollars

Net income (loss)

48,508,000 US dollars

Contract revenue

2,683,000 US dollars

Income

5,000,000 US dollars

Qarziba

6,150,000 US dollars

Ohtuvayre inventors

3,294,000 US dollars

Other

1,226,000 US dollars

Filspari

13,567,000 US dollars

Kyprolis

7,044,000 US dollars

Ohtuvayre

4,144,000 US dollars

Rylaze

3,201,000 US dollars

Capvaxive

2,316,000 US dollars

Vaxneuvance

1,351,000 US dollars

Teriparatide injection

1,470,000 US dollars

Other

4,269,000 US dollars

Captisol

7,978,000 US dollars

Cost of Captisol

3,214,000 US dollars

Amortization of intangibles

8,097,000 US dollars

Research and development

14,668,000 US dollars

General and administrative

29,123,000 US dollars

Fair value adjustments to partner program derivatives

0 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.